[Reduction of cisplatin toxicity by fosfomycin in animal models].
The protective effect of fosfomycin against cisplatin-induced toxicities was studied in rats. A total of 64 Fischer rats were injected intravenously with daily doses of 1, 2, 5 and 10 mg/kg of cisplatin with or without 300 mg/kg of fosfomycin for a period varying from 1 to 10 days. The same total dose of 10 mg/kg of cisplatin was given to all animals. Cisplatin-induced toxic side-effects of body weight loss, nephrotoxicity and ototoxicity were significantly reduced functionally or histopathologically by the combined administration of cisplatin and fosfomycin. A comparison of different dosage schedules with a total dose of 10 mg/kg of cisplatin showed that a higher daily dose for a shorter time period produced more marked toxicities.
D000410:Alanine Transaminase / Q000097:blood; D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001219:Aspartate Aminotransferases / Q000097:blood; D001798:Blood Proteins / Q000032:analysis; D001806:Blood Urea Nitrogen; D001835:Body Weight / Q000187:drug effects; D002945:Cisplatin / Q000378:metabolism / Q000633:toxicity*; D003404:Creatinine / Q000097:blood; D004305:Dose-Response Relationship, Drug; D004432:Ear, Middle / Q000187:drug effects / Q000473:pathology; D005578:Fosfomycin / Q000008:administration & dosage / Q000494:pharmacology*; D007668:Kidney / Q000187:drug effects / Q000473:pathology; D008297:Male; D051381:Rats; D011916:Rats, Inbred F344
D000900:Anti-Bacterial Agents; D001798:Blood Proteins; D005578:Fosfomycin; D003404:Creatinine; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D002945:Cisplatin